Enhanced prognostic evaluation of diffuse large B‐cell lymphoma: A comprehensive surveillance study incorporating Epstein–Barr virus infection status and immunohistochemical markers

Abstract Emerging biologic subsets and new prognostic markers are significantly important for aggressive diffuse large B‐cell lymphoma (DLBCL). Nevertheless, the high cost of testing limits the availability of these tests in most hospitals, thus making prognostic judgment based on basic immunohistochemical testing, whole blood Epstein–Barr virus DNA (WBEBV) surveillance and clinical features advantageous for hospitals and patients with poor medical conditions. We included 647 DLBCL patients treated in our hospital from January 2009 to March 2023. Non‐germinal center B‐cell like, Ki‐67, and International Prognostic Index (IPI) scores were related to cMYC/B‐cell lymphoma 2 (Bcl‐2)‐double expression. Age, Epstein–Barr virus‐encoded small RNA (EBER) positivity, and IPI scores were associated with mortality. The cutoffs for differential overall survival (OS) of age, WBEBV, Bcl‐2, and cMYC were 57 years, 1514 copies/mL (baseline), 5.89 × 10 4 copies/mL (treatment), 40%, and 55%, respectively. EBER positivity was significantly associated with a worse OS. Patients with newly defined DE (Bcl‐2 ≥ 40 and cMYC > 55) had a worse prognosis than controls ( p = 0.04). We found that cMYC with an optimal cutoff of 47.5 could effectively predict high‐grade DLBCL with an area under the curve of 0.912, and the specificity and sensitivity were 70.7% and 100%, respectively. Our study provides valuable insights into the prognostic factors and biomarker cutoffs that influence OS in DLBCL patients, which may guide clinicians in tailoring treatment strategies and improving patient outcomes.